A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

You may be eligible if

• Applicable for Part 1 participants:
• Age 6 years and older, at the time of signing the informed consent
• Physician diagnosis of asthma for at least 12 months
• Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
• Participant or legally authorized representative (where applicable) has consented to participate
• Applicable for Part 2 participants:
• Age 18 years and older, at the time of signing the informed consent.
• Physician diagnosis of asthma for at least 12 months
• Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
• Participant or legally authorized representative (where applicable) has consented to participate
• Participants must meet the criteria for at least one of the cohorts below:
• A) Asthma control cohorts
• 1. ACQ-5 \>= 1.5
• 2. ACQ-5 \< 1.5 (B) Type-2 biomarker cohorts
• 3. Elevated T2 biomarkers (B1: Type-2-high cohort)
• 4. Low T2 biomarkers (B2: Type-2-low cohort)
• Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):
• Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
• Participants with moderate/severe cognitive impairment.
• Participants with moderate/severe cardiac disease.
• Participants on immunosuppressive medication for a chronic condition.
• Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)
• The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.